Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.
- 1Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany.
- 2Institute of Human Genetics, Heinrich-Heine University, Duesseldorf, Germany.
Abstract
This retrospective study involving 155 patients from the Düsseldorf MDS Registry compared cytogenetic banding from peripheral blood (PB) and bone marrow (BM) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). For 63 of these patients, paired PB and BM cytogenetic analyses were available that were conducted no more than 3 months apart. Concordant ISCN results were found in 81%, with no significant differences in the total number of metaphases or aberrant metaphases between PB and BM. Furthermore, IPSS-R/-M scorings, derived from PB and BM, turned out to be comparable, with only 7 out of 63 patients classified into a different cytogenetic risk category. This implies that aberrant clones are not underrepresented in PB and that cytogenetic findings from PB can reliably reflect those obtained from BM.
Related
- Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesions.
- Bilateral Adrenal Masses, Extreme Catecholamine Excess, and Hypercalcitoninemia With Metastatic Neuroendocrine Neoplasia: A Diagnostic Dilemma
- Diagnostic accuracy of a systematic approach using Swedescore versus conventional colposcopy for the detection of cervical intraepithelial neoplasia grade 2 or worse: A multicenter, non‐randomized clinical study
- Development of a Novel Real-Time Computer-Assisted Colonoscopy Diagnostic Tool for Colorectal Neoplasia and Cancer to Enable Personalized Patient Management: Protocol for a Multicenter Proof-of-Concept Study.
- Rapid and reproducible karyotyping with long-read sequencing in patients with AML∗†
BibTeX
@article{heusler2026banding,
title = {{Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.}},
author = {Cornelia Heusler and Barbara Hildebrandt and Felicitas Schulz and Kathrin Nachtkamp and Corinna Strupp and Valerie Flatten and Sascha Dietrich and Norbert Gattermann and Ulrich Germing},
journal = {Genes, chromosomes \& cancer},
year = {2026},
month = oct,
doi = {10.1002/gcc.70177},
url = {https://europepmc.org/article/MED/42852862},
note = {CC BY},
}
RIS
TY - JOUR
TI - Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.
AU - Cornelia Heusler
AU - Barbara Hildebrandt
AU - Felicitas Schulz
AU - Kathrin Nachtkamp
AU - Corinna Strupp
AU - Valerie Flatten
AU - Sascha Dietrich
AU - Norbert Gattermann
AU - Ulrich Germing
PY - 2026
DA - 2026/10/01
JO - Genes, chromosomes & cancer
DO - 10.1002/gcc.70177
UR - https://europepmc.org/article/MED/42852862
AB - This retrospective study involving 155 patients from the Düsseldorf MDS Registry compared cytogenetic banding from peripheral blood (PB) and bone marrow (BM) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). For 63 of these patients, paired PB and BM cytogenetic analyses were available that were conducted no more than 3 months apart. Concordant ISCN results were found in 81%, with no significant differences in the total number of metaphases or aberrant metaphases between PB and BM. Furthermore, IPSS-R/-M scorings, derived from PB and BM, turned out to be comparable, with only 7 out of 63 patients classified into a different cytogenetic risk category. This implies that aberrant clones are not underrepresented in PB and that cytogenetic findings from PB can reliably reflect those obtained from BM.
SN - 1045-2257
SN - 1098-2264
ER -